Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4790468 | 0.94 | HPGD (0.41) | GRM5HPGDALDH1A1LMNAKDM4E | |
| SCHEMBL4790072 | 0.91 | GRM5 (0.44) | GRM5HPGDALDH1A1LMNAKDM4E | |
| SCHEMBL4790002 | 0.91 | HPGD (0.43) | GRM5HPGDALDH1A1LMNAKDM4E | |
| SCHEMBL4789879 | 0.90 | GRM5 (0.43) | GRM5HPGDALDH1A1LMNAKDM4E | |
| SCHEMBL4758582 | 0.90 | GRM5 (0.46) | GRM5HPGDALDH1A1LMNAKDM4E | |
| SCHEMBL4789634 | 0.90 | TDP1 (0.47) | GRM5HPGDALDH1A1KDM4EMEN1 | |
| SCHEMBL4758742 | 0.89 | GRM5 (0.43) | GRM5HPGDALDH1A1LMNAKDM4E | |
| SCHEMBL4789179 | 0.88 | GRM5 (0.43) | GRM5HPGDALDH1A1LMNATDP1 | |
| SCHEMBL4756503 | 0.88 | GRM5 (0.44) | GRM5HPGDALDH1A1LMNAKDM4E | |
| SCHEMBL4789910 | 0.85 | GRM5 (0.41) | GRM5HPGDALDH1A1LMNAALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | claimed |
| WO-2008015271-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THE USE AS A MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015271-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THE USE AS A MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | disclosed |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | disclosed |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRIK5 | GRM5 1/4885HPGD 1132/4885ALDH1A1 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.